Clinical Trial of New Drug For SCI
Planned For Fall 2022 in Chicago
By Stephanie Lollino
March 2, 2022
Editor’s Note: There was an overwhelming response to our blogpost about NVG-291, a promising new drug which may enable the spinal cord to repair itself. The article prompted more views and comments than we have ever had on a single subject. Hundreds the of responses came from people around the world who were eager for more information. So we reached out to the Principal Investigator of the clinical trial, Dr. Monica Perez, of the Shirley Ryan AbilityLab in Chicago, for more specifics – including when the trial is set to begin and how to contact researchers if you’re interested. We will also continue to bring you updates on the trial as they become available.
NVG-291, a new injectable drug that could help people with spinal cord injuries recover feeling and mobility, is intended to be used in human clinical trials later this year at the Shirley Ryan AbilityLab in Chicago. “The ability of NVG-291 to demonstrate meaningful recovery in motor function, sensory function and bladder control in animal models is exceptional. If these results translate to patients, NVG-291 could redefine the treatment of spinal cord injury,” says Dr. Monica A. Perez, Principal Investigator at Shirley Ryan AbilityLab.
“Participants will be given injections each day for approximately 12 weeks.” Dr. Perez explains. “These injections, we hope, at some point will be able to be self-administered – and if successful, be used at home. One of the important aspects of this single-center trial is that we will use novel methods to assess connections from the brain to the spinal cord and behavioral outcomes.”
Dr. Perez sums up; “If the drug is effective, it would provide an easy-to-use alternative for recovery of movement and feeling. But, right now, it’s just too early to say.”
For information about the trial, contact Sri Vemulakonda ([email protected]). The researchers are creating a registry of people who want to be involved either initially or in a second phase.
Dr. Monica Perez, Scientific Chair, Arms + Hands Lab, Shirley Ryan AbilityLab | Professor of Physical Medicine and Rehabilitation, Northwestern University, Research Scientist Edward Hines Jr., VA Hospital [email protected], @MonicaPerezPhD
For more on NVG-291: https://facingdisability.com/blog/new-drug-enables-spinal-cord-to-repair-itself